Search
Oral Presentation
Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.
Tabernero J, Prager G, Fakih M, et al.
Poster Presentation
Management of futibatinib-associated adverse events in patients with advanced cancers: Results of a pooled analysis.
Meric-Bernstam F, Hollebecque A, Furuse J, et al.
Poster Presentation
Real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: A retrospective observational study using an administrative database.
Shinozaki E, Kagawa Y, Okude R, et al.
Poster Presentation
Multicenter retrospective study of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for vulnerable patients with pretreated metastatic colorectal cancer (mCRC): WJOG14520G (TWILIGHT).
Mitani S, Kito Y, Kawakami H, et al.
Poster Presentation
Updated analysis: Alternative biweekly dosing schedule of Trifluridine-Tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients with previously treated metastatic colorectal cancer
Cann C, LaPelusa M, Cimino S, et al.